Dialysis adequacy, residual renal function and serum concentrations of selected low molecular weight proteins in patients undergoing continuous ambulatory peritoneal dialysis

Medical Science Monitor

Volumn 9, Issue 11, 2003, Pages

  Stompór, Tomasz ^a,b   Sułowicz, Władysław ^a   Anyszek, Tomasz ^b   Kuśnierz, Beata ^b   Fedak, Danuta ^b   Naskalski, Jerzy ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Acid RNA se; Alkaline RNA se; Peritoneal dialysis; Uremic toxins

Indexed keywords

ALPHA 1 MICROGLOBULIN; CREATININE; LOW MOLECULAR WEIGHT PROTEIN; PANCREATIC RIBONUCLEASE; PROTEIN; RIBONUCLEASE; RIBONUCLEASE II; UNCLASSIFIED DRUG; UREMIC TOXIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; MOLECULAR WEIGHT; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY; UREMIA;

ALPHA-GLOBULINS; CREATINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KIDNEY; MIDDLE AGED; MOLECULAR WEIGHT; RENAL DIALYSIS; RIBONUCLEASES; SPECTROPHOTOMETRY; TIME FACTORS;

EID: 1642442598     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol, 1999; 10: 1815-1823
2. Vanholder R, De Smet R, Vogeleere P, Ringoir S: Middle molecules: toxicity and removal by hemodialysis and related strategies. Artif Organs, 1995; 19: 1120-1225
3. Selgas R, Bajo MA, Fernandez-Reyes MJ et al.: An analysis of adequacy of dialysis in a selected population on CAPD for over 3 years: the influence of urea and creatinine kinetics. Nephrol Dial Transplant, 1993; 8: 1244-1253
4. Teehan BP, Schleifer CR, Brown JM et al.: Urea kinetic modeling and clinical outcome. A five year longitudinal study. In: Khanna R (ed.) Advances in continuous ambulatory peritoneal dialysis. Perit Dial Bull Inc. Toronto, 1990; 6: 181-185
5. Keshaviah PR, Nolph KD, Van Stone JC: The peak concentration hypothesis. A urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Perit Dial Int, 1989; 9: 257-260
6. Genestier S, Hedelin G, Schaffer P, Faller B: Prognostic factors in CAPD: a retrospective study of 10-year period. Nephrol Dial Transplant, 1995; 10: 1905-1911
7. Rabin E, Algom D, Freedman M et al.: Ribonuclease activity in renal failure. Evidence of toxicity. Nephron, 1991; 27: 254-259
8. Kult J, Dragoun G: Low molecular serum proteins in uremic patients. In: Heidland A, Hennemann H, Kult J. (Ed.) Renal insufficiency. Georg Thiemes Publishers, Stuttgart, 1976; 115-120
9. 1-microglobulin in the urine and serum in proteinuria and kidney insufficiency. Klin Wochenschr, 1985; 63: 711-717
10. Naskalski JW, Ekiert - Kubinyi M, Krzemień D: Serum ribonuclease activity in dialyzed patients with terminal renal failure. Acta Med Pol, 1986; 27: 3-4
11. Naskalski J, Krzemień D: Accumulation of low molecular weight proteins in patients treated with hemodialysis. Nephron, 1993; 63: 484
12. Jung K, Schulze BD, Sydow K et al.: Diagnostic value of low-molecular mass proteins in serum for the detection of reduced glomerular filtration rate. J Clin Chem Clin Biochem, 1987; 25: 499-503
13. Itoh Y, Enomoto H, Takagi K, Kawai T: Clinical usefulness of serum α1-microglobulin as a sensitive indicator for renal insufficiency. Nephron, 1983; 35: 211-212
14. Marczewski KT, Krawczyk W, Grzywna R et al.: Particular fractions of microproteinuria in patients with stabile angina pectoris and without a clinical nephropathy. Med Sci Monit, 2000; 6: 93-5
15. 2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-α therapy. Med Sci Monit, 2002; 8: CR538-42
16. Yavuz S, Ayabakan N, Goncu MT, Ozdemir IA: Effect of combined dopamine and diltiazem on renal function after cardiac surgery. Med Sci Monit, 2002; 8: PI45-50
17. Naskalski JW, Celiński A: Determining of acid and alkaline ribonuclease in human serum and urine. Math Med Pol, 1992; 78: 107-110
18. Twardowski ZJ, Nolph KD, Khanna R: Peritoneal Equilibration Test. Perit Dial Bull, 1987; 7: 138-147
19. 2-microglobulin in CAPD. Adv Perit Dial, 1992; 8: 369-372
20. Amici G, Virga G, Da Rin G et al.: Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron, 1993; 65: 469-471
21. 2-microglobulin: its significance in the evaluation of renal function. Kidney Int, 1987; 32: 635-641
22. Horl W, Johum M, Heidland A, Fritz H: Release of granulocyte proteinase during hemodialysis. Am J Nephrol, 1983; 3: 213-217
23. Horl W, Schafer RM, Heidland A: Effect of different dialysers on proteinases and proteinase inhibitors during hemodialysis. Am J Nephrol, 1985; 5: 320-325
24. Luciak M, Tchorzewski H, Trznadel K: Release of neutrophil granule factors during early periods of hemodialysis. A possible cause of haemodialysis neutropenia. Nephron, 1984; 37: 30-34
25. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis: association with clinical outcomes J Am Soc Nephrol, 1996; 7: 198-207
26. Lameire NH: The impact of residual renal function on the adequacy of peritoneal dialysis. Nephron, 1997; 77: 13-28
27. Lopez-Menchero R, Miguel A, Garcia-Ramon R et al.: Importance of residual renal function in continuous ambulatory peritoneal dialysis: its influence on different parameters of renal replacement treatment. Nephron, 1999; 83: 219-225
28. Paniagua R, Amato D, Vonesh E et al.: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol, 2002; 13: 1307-1320